Jason P Sulkowski1, Kristine M Nacion2, Katherine J Deans1, Peter C Minneci1, Marc A Levitt3, Hayat M Mousa4, Seth A Alpert5, Steven Teich6. 1. Center for Surgical Outcomes Research, The Research Institute Nationwide Children's Hospital, Columbus, OH; Center for Colorectal and Pelvic Reconstruction, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, Columbus, Columbus, OH. 2. Center for Surgical Outcomes Research, The Research Institute Nationwide Children's Hospital, Columbus, OH. 3. Center for Colorectal and Pelvic Reconstruction, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, Columbus, Columbus, OH. 4. Center for Colorectal and Pelvic Reconstruction, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, Columbus, Columbus, OH; Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH. 5. Center for Colorectal and Pelvic Reconstruction, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, Columbus, Columbus, OH; Division of Pediatric Urology, Department of Surgery, Nationwide Children's Hospital, Columbus, OH. 6. Center for Colorectal and Pelvic Reconstruction, Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, Columbus, Columbus, OH. Electronic address: steven.teich@nationwidechildrens.org.
Abstract
PURPOSE: This study describes our series of children with bowel and bladder dysfunction (BDD) treated with sacral nerve stimulation in order to begin to identify characteristics associated with better outcomes and guide future therapies. METHODS: Between May 2012 and February 2014, 29 patients were evaluated before and after sacral nerve stimulator (SNS) placement. A prospective data registry was developed that contains clinical information and patient-reported measures: Fecal Incontinence Qualify of Life Scale, Fecal Incontinence Severity Scale, PedsQL Gastrointestinal Symptom Scale, and Vancouver DES Symptom Scale. RESULTS: The median age of patients was 12.1 (interquartile range: 9.4, 14.3) years and the median follow-up period was 17.7 (12.9, 36.4) weeks. 93% had GI complaints and 65.5% had urinary symptoms while 7% had urologic symptoms only. The most common etiologies of BBD were idiopathic (66%) and imperforate anus (27%). Five patients required reoperation due to a complication with battery placement. Six of 11 patients (55%) with a pre-SNS cecostomy tube no longer require an antegrade bowel regimen as they now have voluntary bowel movements. Ten of eleven patients (91%) no longer require anticholinergic medications for bladder overactivity after receiving SNS. Significant improvements have been demonstrated in all four patient-reported instruments for the overall cohort. CONCLUSIONS: Early results have demonstrated improvements in both GI and urinary function after SNS placement in pediatric patients with bowel and bladder dysfunction.
PURPOSE: This study describes our series of children with bowel and bladder dysfunction (BDD) treated with sacral nerve stimulation in order to begin to identify characteristics associated with better outcomes and guide future therapies. METHODS: Between May 2012 and February 2014, 29 patients were evaluated before and after sacral nerve stimulator (SNS) placement. A prospective data registry was developed that contains clinical information and patient-reported measures: Fecal Incontinence Qualify of Life Scale, Fecal Incontinence Severity Scale, PedsQL Gastrointestinal Symptom Scale, and Vancouver DES Symptom Scale. RESULTS: The median age of patients was 12.1 (interquartile range: 9.4, 14.3) years and the median follow-up period was 17.7 (12.9, 36.4) weeks. 93% had GI complaints and 65.5% had urinary symptoms while 7% had urologic symptoms only. The most common etiologies of BBD were idiopathic (66%) and imperforate anus (27%). Five patients required reoperation due to a complication with battery placement. Six of 11 patients (55%) with a pre-SNS cecostomy tube no longer require an antegrade bowel regimen as they now have voluntary bowel movements. Ten of eleven patients (91%) no longer require anticholinergic medications for bladder overactivity after receiving SNS. Significant improvements have been demonstrated in all four patient-reported instruments for the overall cohort. CONCLUSIONS: Early results have demonstrated improvements in both GI and urinary function after SNS placement in pediatric patients with bowel and bladder dysfunction.
Authors: Dayo O Adewole; Mijail D Serruya; James P Harris; Justin C Burrell; Dmitriy Petrov; H Isaac Chen; John A Wolf; D Kacy Cullen Journal: Crit Rev Biomed Eng Date: 2016
Authors: Stephen Yang; Michael E Chua; Stuart Bauer; Anne Wright; Per Brandström; Piet Hoebeke; Søren Rittig; Mario De Gennaro; Elizabeth Jackson; Eliane Fonseca; Anka Nieuwhof-Leppink; Paul Austin Journal: Pediatr Nephrol Date: 2017-10-03 Impact factor: 3.714
Authors: Mana H Vriesman; Ilan J N Koppen; Michael Camilleri; Carlo Di Lorenzo; Marc A Benninga Journal: Nat Rev Gastroenterol Hepatol Date: 2019-11-05 Impact factor: 46.802
Authors: Aart A van der Wilt; Bart P W van Wunnik; Rosel Sturkenboom; Ingrid J Han-Geurts; Jarno Melenhorst; Marc A Benninga; Cor G M I Baeten; Stephanie O Breukink Journal: Int J Colorectal Dis Date: 2016-06-13 Impact factor: 2.571
Authors: Mana H Vriesman; Lyon Wang; Candice Park; Karen A Diefenbach; Marc A Levitt; Richard J Wood; Seth A Alpert; Marc A Benninga; Karla Vaz; Desale Yacob; Carlo Di Lorenzo; Peter L Lu Journal: Neurogastroenterol Motil Date: 2020-02-03 Impact factor: 3.598